Nov. 12 at 5:40 PM
After a rocky 2024, the psychedelics industry is showing powerful signs of renewal—2025 may be remembered as its watershed year.
🔹 Record Funding Resurgence — 4Q25 has already seen
$580M raised, the strongest quarter since 2021, driven by MindMed, Cybin, and Atai Beckley in fewer, larger, late-stage financings.
🔹 Big Pharma Steps In — AbbVie’s
$1.2B acquisition of Gilgamesh’s depression program marks a major validation moment for the field.
🔹 Clinical Progress Builds Confidence — Multiple players, including Compass Pathways, Cybin, MindMed, Atai Beckley, and GH Research, are advancing to Phase 3 trials after key Phase 2 successes.
🔹 Investor Momentum Returns — The PSIL ETF is up ~70% YTD, reflecting renewed conviction in psychedelics’ long-term potential.
2025 could mark the beginning of a new era for psychedelic medicine. Follow along with Robert Sassoon!
https://www.watertowerresearch.com/doc?docID=IR_Neuro_11102025
#Psychedelics #MentalHealth #Biotech #LifeSciences #Atai #Cybin
$CYBN $MNMD $GRHS $CMPS